Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

Background Patients with non-alcoholic steatohepatitis (NASH) have increased mortality and liver-related complications. In contrast, simple steatosis is considered benign and non-progressive. Objective To investigate disease progression in patients with different degrees of non-alcoholic fatty liver disease (NAFLD) activity. Design Prospective longitudinal hospital-based cohort study. Patients Fifty-two patients (age 44±9 years) with biopsy-proven NAFLD had liver biopsies repeated at month 36. Results Among 13 patients with simple steatosis at baseline, 2 (15%) had a normal liver at month 36, 3 (23%) continued to have simple steatosis, 5 (39%) developed borderline NASH and 3 (23%) developed NASH. Among 22 patients with borderline NASH at baseline, 4 (18%) had simple steatosis and 13 (59%) had borderline NASH at month 36, while 5 (23%) developed NASH. Among 17 patients with NASH at baseline, 10 (59%) continued to have NASH and 6 (35%) had borderline NASH at month 36. Only 1 (6%) patient regressed to simple steatosis. Overall, 14 (27%) patients had fibrosis progression, 25 (48%) had static disease, and 13 (25%) had fibrosis regression. Reduction in body mass index and waist circumference was independently associated with non-progressive disease activity and fibrosis. The baseline serum levels and month 36 changes in adiponectin, tumour necrosis factor α, interleukin 6 and leptin were not associated with disease progression. Serum cytokeratin-18 fragment level reflected disease activity and its change correlated with the change in NAFLD activity score (R=0.51, p<0.001). Conclusions Patients with simple steatosis may still develop NASH and fibrosis progression. Weight reduction is associated with non-progressive disease. All patients with NAFLD should undergo periodic assessment and lifestyle modification.

[1]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[2]  I. Guha,et al.  Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease , 2006, Gut.

[3]  S. Caldwell,et al.  Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[4]  J. Kench,et al.  Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.

[5]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[6]  H. J. de Silva,et al.  How should we manage patients with non‐alcoholic fatty liver disease in 2007? , 2007, Journal of gastroenterology and hepatology.

[7]  P. Hayashi,et al.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study , 2003, American Journal of Gastroenterology.

[8]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[9]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease , 2006 .

[10]  G. Bedogni,et al.  Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis , 2008, Gut.

[11]  I. Guha,et al.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.

[12]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[13]  V. Wong,et al.  Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.

[16]  J. Newton,et al.  Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance , 2008, Gut.

[17]  A. Bauman,et al.  Independent effects of physical activity in patients with nonalcoholic fatty liver disease , 2009, Hepatology.

[18]  F. Chan,et al.  Clinical and histological features of non‐alcoholic fatty liver disease in Hong Kong Chinese , 2004, Alimentary pharmacology & therapeutics.

[19]  A. Feldstein,et al.  Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study , 2009, Hepatology.

[20]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.

[21]  Julien Vergniol,et al.  Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.

[22]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[23]  F. Chan,et al.  Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non‐alcoholic fatty liver disease , 2006, Alimentary pharmacology & therapeutics.

[24]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[25]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[26]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[27]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[28]  J. George,et al.  Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss , 2009, Hepatology.

[29]  R. N. Macsween,et al.  Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? , 2002, Journal of clinical pathology.

[30]  Jun Yu,et al.  Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese , 2010, The American Journal of Gastroenterology.

[31]  J. Sung,et al.  Histological progression of non‐alcoholic fatty liver disease in Chinese patients , 2005, Alimentary pharmacology & therapeutics.

[32]  Randall G. Lee,et al.  Nonalcoholic steatohepatitis: a study of 49 patients. , 1989, Human pathology.

[33]  I. Guha,et al.  Future use of the Glasgow alcoholic hepatitis score. , 2006, Gut.

[34]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[35]  V. Wong,et al.  Can dietetic intervention for obesity ever succeed in real life? , 2007, Journal of gastroenterology and hepatology.

[36]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[37]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[38]  S. Ryu,et al.  Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men , 2009, Gut.